These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15001601)

  • 1. Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes.
    Winkler K; Abletshauser C; Friedrich I; Hoffmann MM; Wieland H; März W
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1153-9. PubMed ID: 15001601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action.
    Winkler K; Abletshauser C; Hoffmann MM; Friedrich I; Baumstark MW; Wieland H; März W
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5485-90. PubMed ID: 12466341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype.
    März W; Scharnagl H; Abletshauser C; Hoffmann MM; Berg A; Keul J; Wieland H; Baumstark MW
    Circulation; 2001 Apr; 103(15):1942-8. PubMed ID: 11306521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of fluvastatin slow-release (XL 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes.
    Bevilacqua M; Righini V; Barrella M; Vago T; Chebat E; Dominguez LJ
    Adv Ther; 2005; 22(6):527-42. PubMed ID: 16510370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis.
    Ballantyne CM; Pazzucconi F; Pintó X; Reckless JP; Stein E; McKenney J; Bortolini M; Chiang YT
    Clin Ther; 2001 Feb; 23(2):177-92. PubMed ID: 11293552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events.
    Stojakovic T; de Campo A; Scharnagl H; Sourij H; Schmölzer I; Wascher TC; März W
    Eur J Clin Invest; 2010 Mar; 40(3):187-94. PubMed ID: 20067513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
    Stein EA; Ballantyne CM; Windler E; Sirnes PA; Sussekov A; Yigit Z; Seper C; Gimpelewicz CR
    Am J Cardiol; 2008 Feb; 101(4):490-6. PubMed ID: 18312764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
    Bays H; Giezek H; McKenney JM; O'Neill EA; Tershakovec AM
    Metab Syndr Relat Disord; 2012 Aug; 10(4):260-6. PubMed ID: 22400810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.
    Betteridge DJ; Durrington PN; Fairhurst GJ; Jackson G; McEwan MS; McInnes GT; Miller JP; Mir MA; Reckless JP; Rees-Jones DI
    Am J Med; 1994 Jun; 96(6A):45S-54S. PubMed ID: 8017467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients.
    Kom GD; Schwedhelm E; Maas R; Schneider L; Benndorf R; Böger RH
    Br J Clin Pharmacol; 2007 Jun; 63(6):672-9. PubMed ID: 17214829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect.
    Milionis HJ; Tambaki AP; Kanioglou CN; Elisaf MS; Tselepis AD; Tsatsoulis A
    Thyroid; 2005 May; 15(5):455-60. PubMed ID: 15929667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
    Mendoza S; Gamez R; Mas R; Goicochea E
    Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group.
    Dallongeville J; Fruchart JC; Pfister P; Bard JM
    J Intern Med Suppl; 1994; 736():95-101. PubMed ID: 7986315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of fluvastatin-extended release in hypercholesterolemic patients: morning administration is equivalent to evening administration.
    Scharnagl H; Vogel M; Abletshauser C; Freisinger F; Stojakovic T; März W
    Cardiology; 2006; 106(4):241-8. PubMed ID: 16691029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study.
    Winkler K; Winkelmann BR; Scharnagl H; Hoffmann MM; Grawitz AB; Nauck M; Böhm BO; März W
    Circulation; 2005 Mar; 111(8):980-7. PubMed ID: 15710755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin.
    Papavasiliou EC; Gouva C; Siamopoulos KC; Tselepis AD
    Nephrol Dial Transplant; 2006 May; 21(5):1270-7. PubMed ID: 16421163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration.
    Zhang B; Fan P; Shimoji E; Itabe H; Miura S; Uehara Y; Matsunaga A; Saku K
    Atherosclerosis; 2006 Jun; 186(2):291-301. PubMed ID: 16154574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study.
    Norby GE; Holme I; Fellström B; Jardine A; Cole E; Abedini S; Holdaas H;
    Arthritis Rheum; 2009 Apr; 60(4):1060-4. PubMed ID: 19333947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.